Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Treatment Study
100%
Antiretroviral Therapy
100%
Strategic Timing
100%
Rationale Design
100%
AIDS/HIV
70%
Human Immunodeficiency Virus Infection
30%
CD4 Count
30%
Clinical Management
20%
International Trial
20%
Accruals
20%
Non-AIDS Comorbidities
20%
Challenges Encountered
20%
Virus Diseases
10%
Human Immunodeficiency Virus Type 1 (HIV-1)
10%
Lessons Learned
10%
Clinical Practice Guidelines
10%
First Year
10%
Cardiovascular Disease
10%
CD4+ T
10%
Infected Individual
10%
Lymphocytes
10%
Population Change
10%
Successful Completion
10%
Renal Disease
10%
Early Antiretroviral Therapy
10%
Major Components
10%
Infection-viral
10%
Nave
10%
Liver Disease
10%
Regulatory Requirements
10%
Change in Treatment
10%
Combined Antiretroviral Therapy (cART)
10%
Opportunistic Diseases
10%
Publicly Funded
10%
Viral Eradication
10%
Limited Amount of Data
10%
Wider Population
10%
Unanswerable Questions
10%
Medicine and Dentistry
Acquired Immune Deficiency Syndrome
100%
Human Immunodeficiency Virus Infection
50%
Human Immunodeficiency Virus
50%
Clinical Management
33%
Diseases
33%
Virus Infection
16%
Cancer
16%
Antiretroviral Therapy
16%
Cardiovascular Disease
16%
Nephropathy
16%
Study Participant
16%
Morbidity
16%
Liver Disease
16%
Viral Clearance
16%
Human Immunodeficiency Virus 1
16%
CD4+ T Lymphocyte
16%
Population Dynamics
16%
Mathematics
Optimal Time
100%
Primary Endpoint
100%
Successful Completion
100%
Randomization
100%
Pharmacology, Toxicology and Pharmaceutical Science
Acquired Immune Deficiency Syndrome
100%
HIV
50%
Human Immunodeficiency Virus Infection
50%
Diseases
33%
Morbidity
16%
Virus Infection
16%
Liver Disease
16%
Kidney Disease
16%
Human Immunodeficiency Virus 1
16%
Viral Clearance
16%
Cardiovascular Disease
16%